AU2014225678B2 - Host cells and methods of use - Google Patents

Host cells and methods of use Download PDF

Info

Publication number
AU2014225678B2
AU2014225678B2 AU2014225678A AU2014225678A AU2014225678B2 AU 2014225678 B2 AU2014225678 B2 AU 2014225678B2 AU 2014225678 A AU2014225678 A AU 2014225678A AU 2014225678 A AU2014225678 A AU 2014225678A AU 2014225678 B2 AU2014225678 B2 AU 2014225678B2
Authority
AU
Australia
Prior art keywords
host cell
variant
glp
protein
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014225678A
Other languages
English (en)
Other versions
AU2014225678A1 (en
Inventor
Yonghwan JIN
Yuan Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of AU2014225678A1 publication Critical patent/AU2014225678A1/en
Application granted granted Critical
Publication of AU2014225678B2 publication Critical patent/AU2014225678B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0051—Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/04—Oxidoreductases acting on sulfur groups as donors (1.8) with a disulfide as acceptor (1.8.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/04—Intramolecular oxidoreductases (5.3) transposing S-S bonds (5.3.4)
    • C12Y503/04001—Protein disulfide-isomerase (5.3.4.1), i.e. disufide bond-forming enzyme

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
AU2014225678A 2013-03-06 2014-03-06 Host cells and methods of use Ceased AU2014225678B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361773329P 2013-03-06 2013-03-06
US61/773,329 2013-03-06
PCT/US2014/021137 WO2014138371A1 (en) 2013-03-06 2014-03-06 Host cells and methods of use

Publications (2)

Publication Number Publication Date
AU2014225678A1 AU2014225678A1 (en) 2015-09-17
AU2014225678B2 true AU2014225678B2 (en) 2016-11-17

Family

ID=51491943

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014225678A Ceased AU2014225678B2 (en) 2013-03-06 2014-03-06 Host cells and methods of use

Country Status (11)

Country Link
US (1) US9926570B2 (cg-RX-API-DMAC7.html)
EP (1) EP2964666B1 (cg-RX-API-DMAC7.html)
JP (2) JP6742729B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150126839A (cg-RX-API-DMAC7.html)
AU (1) AU2014225678B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015021960A2 (cg-RX-API-DMAC7.html)
CA (1) CA2903739A1 (cg-RX-API-DMAC7.html)
ES (1) ES2843679T3 (cg-RX-API-DMAC7.html)
RU (1) RU2663587C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201504771RA (cg-RX-API-DMAC7.html)
WO (1) WO2014138371A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX364532B (es) 2013-07-04 2019-04-29 Glykos Finland Oy Celulas de hongos filamentosos deficientes de o-manosiltransferasa y metodos de uso de las mismas.
WO2016012468A1 (en) 2014-07-21 2016-01-28 Novartis Ag Production of glycoproteins with mammalian-like n-glycans in filamentous fungi
WO2017112847A1 (en) 2015-12-22 2017-06-29 Albumedix A/S Improved protein expression strains
JP7146637B2 (ja) 2015-12-22 2022-10-04 アルブミディクス リミティド 改善されたタンパク質発現株
CN105950491B (zh) * 2016-05-23 2019-08-06 江南大学 一种高效表达碱性果胶酶的菌株及其构建与应用
ES2906997T3 (es) 2017-06-20 2022-04-21 Albumedix Ltd Cepas de expresión de proteínas mejoradas
KR101984957B1 (ko) * 2017-08-09 2019-06-04 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 효모의 단백질 접힘 기작(protein-folding machinery) 개량을 통한 진세노사이드 생산 증대
US11135276B2 (en) 2019-05-17 2021-10-05 Imam Abdulrahman Bin Faisal University Method of making PDIA2 and compositions containing PDIA2
JP6930670B2 (ja) 2019-06-28 2021-09-01 三菱瓦斯化学株式会社 樹脂組成物、樹脂シート、積層体、樹脂組成物層付き半導体ウェハ、樹脂組成物層付き半導体搭載用基板、及び半導体装置
US20240392279A1 (en) * 2021-09-17 2024-11-28 The University Of North Carolina At Chapel Hill Modified protein disulfide isomerase and uses thereof
GB202301988D0 (en) * 2023-02-13 2023-03-29 Phenotypeca Ltd Breeding process

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077204A (en) 1984-06-21 1991-12-31 Chiron Corporation Yeast endopeptidase for basic amino-acid site cleavage, preparation and use
JP2643968B2 (ja) 1988-02-03 1997-08-25 サントリー株式会社 Ｋｅｘ２エンドプロテアーゼ及びその製造方法
FR2645174B1 (fr) 1989-03-31 1994-01-07 Transgene Sa Souches de levure ameliorees pour la production de proteines heterologues matures en particulier d'hirudine et procede de preparation d'hirudine correspondant
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
GB9015825D0 (en) 1990-07-18 1990-09-05 Ciba Geigy Ag In vitro processing of fusion proteins
DK0548012T3 (da) 1991-12-16 1998-04-14 Ciba Geigy Ag Endoplasmatisk reticulum-placeret rekombinant dibasisk endoprotease samt dens anvendelse
US6291205B1 (en) 1992-06-12 2001-09-18 Merck & Co., Inc. Method of increasing production of disulfide bonded recombinant proteins by saccharomyces cerevisiae
GB9404270D0 (en) 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
GB9411356D0 (en) * 1994-06-07 1994-07-27 Delta Biotechnology Ltd Yeast strains
CA2198968C (en) 1996-03-04 2010-02-09 Toyofumi Masuda Process for production of secretory kex2 derivatives
WO1998001535A1 (en) * 1996-07-05 1998-01-15 Novo Nordisk A/S Method for the production of polypeptides
US7504493B2 (en) 1997-01-23 2009-03-17 The John Hopkins University Characterization of the yeast transcriptome
GB9713412D0 (en) 1997-06-26 1997-08-27 Delta Biotechnology Ltd Improved protein expression strains
WO1999007727A1 (en) * 1997-08-12 1999-02-18 Massachusetts Institute Of Technology Eukaryotic disulfide bond-forming proteins and related molecules and methods
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
GB9902000D0 (en) * 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
EP2261250B1 (en) * 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
AU2005211725B2 (en) 2004-02-09 2010-07-15 Human Genome Sciences, Inc. Albumin fusion proteins
US20060046253A1 (en) * 2004-09-02 2006-03-02 Suntory Limited Method for analyzing genes of industrial yeasts
DE502005005689D1 (de) 2005-05-04 2008-11-27 Signalomics Gmbh Kompetitives n-Hybrid System
HUE029798T2 (en) * 2005-11-04 2017-03-28 Glaxosmithkline Llc Methods of administering hypoglycemic agents
JP5354559B2 (ja) 2005-11-24 2013-11-27 独立行政法人産業技術総合研究所 高効率分泌シグナルペプチド及びそれらを利用したタンパク質発現系
CN103289980A (zh) 2006-07-05 2013-09-11 催化剂生物科学公司 蛋白酶筛选方法及由此鉴别的蛋白酶
US8034607B2 (en) 2007-09-12 2011-10-11 Wisconsin Alumni Research Foundation Methods of enhanced heterologous protein secretion
JP5288379B2 (ja) * 2007-10-31 2013-09-11 独立行政法人産業技術総合研究所 タンパク質の高分泌生産方法
US20100273215A1 (en) 2007-12-21 2010-10-28 Anna Cornelia Hendrika Van Hautum Secretion Yield of a Protein of Interest by in vivo Proteolytic Processing of a Multimeric Precursor
US20110129872A1 (en) * 2009-12-01 2011-06-02 Mogam Biotechnology Research Institute Method for a production of a recombinant protein using yeast co-expression system
RU2427645C1 (ru) * 2010-06-10 2011-08-27 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика") СПОСОБ МИКРОБИОЛОГИЧЕСКОГО СИНТЕЗА ЗРЕЛОГО ИНТЕРФЕРОНА АЛЬФА-2 ЧЕЛОВЕКА, ШТАММ Saccharomyces cerevisiae - ПРОДУЦЕНТ ЗРЕЛОГО ИНТЕРФЕРОНА АЛЬФА-2 ЧЕЛОВЕКА (ВАРИАНТЫ)
MX2015005363A (es) * 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.

Also Published As

Publication number Publication date
RU2663587C2 (ru) 2018-08-07
ES2843679T3 (es) 2021-07-20
RU2015135980A (ru) 2017-04-10
WO2014138371A1 (en) 2014-09-12
EP2964666A4 (en) 2016-08-10
JP2019122395A (ja) 2019-07-25
EP2964666A1 (en) 2016-01-13
AU2014225678A1 (en) 2015-09-17
JP6742729B2 (ja) 2020-08-19
CA2903739A1 (en) 2014-09-12
SG11201504771RA (en) 2015-09-29
BR112015021960A2 (pt) 2017-08-29
US9926570B2 (en) 2018-03-27
JP2016514957A (ja) 2016-05-26
EP2964666B1 (en) 2020-11-18
KR20150126839A (ko) 2015-11-13
US20160017343A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
AU2014225678B2 (en) Host cells and methods of use
EP2401357B1 (en) Host cells and methods of use
KR101262682B1 (ko) 유전자 발현 기술
KR20140114860A (ko) 프로테아제 결핍 사상형 진균 세포들 및 그의 이용방법
KR20140015137A (ko) 분비 효율이 개선된 재조합 단백질의 생산 방법
KR102699074B1 (ko) 재조합 숙주 세포에서 탄소 공급원 조절된 단백질 생산
JP2008543323A (ja) 遺伝子発現技術
CN105377882B (zh) 宿主细胞和使用方法
Liu et al. Targeted introduction of a diphtheria toxin resistant mutation into the chromosomal EF-2 locus of Pichia pastoris and expression of immunotoxin in the EF-2 mutants
US20060121565A1 (en) Methods for increasing the production of a recombinant polypeptide from a host cell
CA3135444C (en) Mut- methylotrophic yeast
EP3947695B1 (en) Mut- methylotrophic yeast
HK40054115A (en) Carbon-source regulated protein production in a recombinant host cell
Ramagoma Development of Yarrowia lipolytica for enhanced production of heterologous proteins
HK40054115B (en) Carbon-source regulated protein production in a recombinant host cell
WO2020200415A1 (en) Mut- methylotrophic yeast

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired